TITLE

M'S SCIENCE INITIATES EUROPEAN PHASE 2 STROKE RECOVERY

PUB. DATE
March 2008
SOURCE
Worldwide Biotech;Mar2008, Vol. 20 Issue 3, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article deals with the clinical trial initiated by M's Science Corporation (MSC), a clinical stage discovery and development company, in Europe with its lead product SA4503 for the treatment of stroke. The target number of patients for this study is 60. The trial aims to evaluate the safety of SA4503 among stroke patients. Particular focus is given to the mechanism of action of SA4503. Comments form Shiro Mita, chairman and chief executive officer (CEO), are included.
ACCESSION #
30001584

 

Related Articles

  • AACR Roundup.  // BioWorld Today;4/21/2009, Vol. 20 Issue 75, p8 

    The article looks at the preclinical data obtained by Medarex Inc. from an ongoing Phase 1 trial of MDX-1401 in patients with relapsed or refractory Hodgkin's lymphoma (HL). Results showed that MDX-1401 has clinical and immunological activity signals. Particular focus is given to the mechanism...

  • The Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder.  // Clinical Drug Investigation;2011 Supplement, Vol. 31 Issue S1, p5 

    No abstract available.

  • Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials. Paoletti, X.; Ezzalfani, M.; Le Tourneau, C. // Annals of Oncology;Sep2015, Vol. 26 Issue 9, p1808 

    Background: More than 95% of published phase I trials have used the 3 + 3 design to identify the dose to be recommended for phase II trials. However, the statistical community agrees on the limitations of the 3 + 3 design compared with model-based approaches. Moreover, the mechanisms of action...

  • Oxaliplatin: a review in the era of molecularly targeted therapy. Alcindor, T.; Beauger, N. // Current Oncology;Feb2011, Vol. 18 Issue 1, p18 

    Objective To review preclinical and clinical data for oxaliplatin in the current context of molecularly targeted therapy. Methods of Study Selection We searched the PubMed and PubChem databases by combining the search terms "oxaliplatin" or "platinum" or both, with "clinical trials,"...

  • PRoFESS Trial Shows No Stroke Benefit.  // Travel Medicine Advisor;Oct2008 Supplement, p2 

    The article cites studies and trials conducted on subjects administered with certain drugs to prevent recurrence of strokes. In the first arm of the PRoFESS trials, authors of the study observed that therapy of 80 mg telmisartan on patients who had suffered ischemic strokes did not lower...

  • Biogen Idec, Cardiokine Begin Phase III Study of Lixivaptan. Hollingsworth, Catherine // BioWorld Today;2/15/2008, Vol. 19 Issue 32, p2 

    The article announces that Biogen Idec and partner Cardiokine Inc. have started enrolling patients in a Phase III trial of lixivaptan, a potential treatment for correcting low sodium serum levels in heart failure patients. The incidence of hyponatremia in patients with heart failure is cited....

  • Multifunctional Actions of Approved and Candidate Stroke Drugs Minnerup, Jens; Schäbitz, Wolf-Rüdiger; Schäbitz, Wolf-Rüdiger // Neurotherapeutics;Jan2009, Vol. 6 Issue 1, p43 

    Summary: Ischemic stroke causes brain damage by multiple pathways. Previous stroke trials have demonstrated that drugs targeting one or only a few of these pathways fail to improve clinical outcome after stroke. Drugs with multimodal actions have been suggested to overcome this challenge. In...

  • CLINIC ROUNDUP.  // BioWorld Today;1/31/2008, Vol. 19 Issue 21, p2 

    This section offers news briefs related to clinical trials. Tigris Pharmaceuticals Inc. has started a multicenter Phase I, ascending-dose clinical study of aminoflavone prodrug for the treatment of cancer. Nuvelo Inc. has initiated Phase I trial to determine the safety, tolerability and...

  • The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma. Pasquali, S.; Mocellin, S. // Current Medicinal Chemistry;Oct2010, Vol. 17 Issue 29, p3327 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics